This is the authors' abstract. We don't add key points for this paper.
Potential conflict of interest: Nothing to report. James E. Squires and Anthony J. Demetris conducted the background literature review and drafted, critically revised, and approved the article. SEE ARTICLE ON PAGE 843 Children who receive a liver transplantation (LT) today have a 94% chance of surviving 5 years with their first graft.(1) Long‐term outcomes up to 20 years after LT are more variable, with graft survival rates ranging from 53% to 77%.(2,3) Causes of late allograft attrition are multifactorial; however, complications related to immunosuppression (both too much and too little) account for most post‐LT morbidity and mortality, and there is growing interest in the contribution of late graft hepatitis and fibrosis. Details regarding the mechanisms driving late allograft pathology remains an area of intense focus, but an ongoing allo‐immune response is felt to be the predominant etiology. Notably, these histological changes can be clinically silent,(4) so their detection often requires a commitment of the transplant team to perform surveillance biopsies (SBs), which must be weighed against the cost and potential risks of the procedure without knowing whether SBs ultimately benefit long‐term outcomes. In this issue of Liver Transplantation, Rocque et al.(5) attempt to bring some clarity to this historically ambiguous subject. The authors show that SBs are not only safe but also they contend the results aid in the clinical management, which impacts outcomes. They report that SBs resulted in no additional biopsy‐related complications but enabled a tailored immunosuppression approach that they associate with improved patient and graft survival. This conclusion should be viewed with cautious optimism. Both immunosuppression increases and decreases were reported, but most SBs resulted in no change of immunosuppression. Without robust follow‐up biopsy and/or serology data that capture ongoing evidence of graft damage (or a lack thereof), the ultimate consequences of changes in immunosuppression are uncertain. This represents an opportunity for future SB analysis. Regarding outcomes, the authors report rejection‐free, graft, and patient survival rates among 3 cohorts (SB, for‐cause biopsy [FCB], and never biopsied [NB]), suggesting improved outcomes in the SB group. There are many possible explanations for this difference, such as selection bias where less well human leukocyte antigen (HLA)–matched or inadequately immunosuppressed recipients, those who experience early T cell–mediated rejection, or those with technical complications are more likely to have elevated liver injury tests and experience FCB. These same complicating factors are potentially contributive in the graft and patient survival analyses. Furthermore, it is unclear in the data presented if a direct comparison between FCB and SB would yield the significant findings reported without the addition of the NB cohort, who demonstrated the worst outcomes of the 3 groups. Finally, other common post‐LT complications attributed to immunosuppression (infection/viremia, posttransplant lymphoproliferative disease, renal dysfunction, etc.) are not presented, limiting the readers’ understanding of how the immunosuppression changes prompted by SBs affected the patients. Ultimately, the report by Rocque et al.(5) adds to the crescendo of data continuing to shed light on the occurrence and management of late graft changes. A current literature review, however, shows the important contributions of HLA matching and the production of donor‐specific antibodies, neither of which were reported in this study.(6,7) Future advancements are needed to better understand the pathophysiologic mechanisms driving histological change. Although SB practices have initially enabled a broader appreciation of the manifestations of late allograft hepatitis and fibrosis, there is an emerging push for more novel, noninvasive modalities(8‐10) that can detect the existence of subclinical liver graft injury. Therefore, although the imaging and biochemical technologies currently available lack the equivalent resolving power of microscopy, there will likely be a future burden placed on the pathologist to provide more value from the specimens they receive so as to truly understand and optimize an individual patient’s immunosuppression, thus mitigating the suspected immune injury driving late allograft injury. One such possibility might be defining “prehistopathological” rejection detected by multiplex immunolabeling of biopsies that facilitate a safe reduction of immunosuppression or the need for continued immunosuppression.(11)
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Squires et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: